Update on Immunohistochemical Analysis in Breast Lesions

Peng, Yan; Butt, Yasmeen M.; Chen, Beiyun; Zhang, Xinmin; Tang, Ping

doi:10.5858/arpa.2016-0482-ra

Cited by 25 publications

(19 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Researchers found a positive correlation between the reduction in E cadherin expression and high Ki 67 expression may be associated with tumor aggressiveness, which provides insight into the role of E cadherin in TNBC tumor biology [6]. However, in the present study, there was no significant association noted between E cadherin expression and Ki 67 expression (p value = 0.977).…”

Section: Discussioncontrasting

confidence: 69%

See 1 more Smart Citation

Expression of E cadherin and Ki 67: Emerging Prognostic Markers in Triple-Negative Breast Cancer

Shetty

Rao

2019

Indian J Surg Oncol

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is an aggressive subgroup of breast cancer which lacks effective target therapy. Expression of biomarkers is one of the important deciding factors for treatment strategies. The aim of this study was to evaluate expression of E cadherin and Ki 67 in relation to clinicopathological features. This prospective observational study included 141 cases of TNBC. Immunohistochemical staining was employed to analyze two biomarkers: E cadherin and Ki 67 on formalin-fixed paraffin-embedded tumor samples obtained from patients defined as TNBC. The age of the patients ranged from 26 to 84 years. Positive lymph nodes were found in 82 (58.1%). The tumor was grade 3 in 105 (74.4%). The E cadherin receptor was positive in 83 (58.8%). The Ki Index was > 10% in 89 (63.12%). The Ki 67 expression was significantly associated with a high nuclear grade (p = 0.000). The significant association noted between loss of E cadherin expression and positive lymph node (p = 0.0296). According to the results, TNBCs are frequently associated with the younger age groups, and the majority is poorly differentiated. The majorities of these have high expression of the Ki 67 and significantly associated with the higher nuclear grade. Loss of E cadherin was significantly associated with positive lymph nodes. Hence, evaluating the expression of E cadherin and Ki 67 routinely would be helpful for evaluating prognostic implications.

show abstract

Section: Discussioncontrasting

confidence: 69%

“…Loss of E cadherin is a fundamental event in the epithelial-mesenchymal transition, which is associated with carcinogenesis of TNBCs. Reduced E cadherin expression may also have a role in the poor prognosis in TNBCs [6].…”

Section: Discussionmentioning

confidence: 99%

Expression of E cadherin and Ki 67: Emerging Prognostic Markers in Triple-Negative Breast Cancer

Shetty

Rao

2019

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…Breast cancer can be divided into subgroups based on expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, which are growth factor receptors that are crucial for proliferation of cancer cells. While targeted therapies antagonizing these receptors have significantly improved the treatment of breast cancers expressing these receptors, treating those that express none of the three receptors, namely triple negative breast cancer (TNBC), remains a daunting challenge [ 1 ]. Chemotherapy is still the mainstream treatment for these cancers.…”

Section: Introductionmentioning

confidence: 99%

CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

BackgroundDoxorubicin-based chemotherapy is currently the most frequently used treatment for triple negative breast cancer (TNBC), yet the response rate is not high due to the lack of a biomarker allowing identification of responsive patients before the chemotherapy is initiated. We have demonstrated that doxorubicin inhibits proliferation of cancer cells through proteolytic activation of a transcription factor called CREB3L1 (cAMP response element binding protein 3-like 1), and that CREB3L1 expression in cancer cells is a key determinant of their sensitivity to doxorubicin when they are cultured in vitro or established as xenograft tumors in mice. The purpose of this study is to determine whether CREB3L1 expression in tumor cells of TNBC patients can be established as a biomarker to predict outcomes of doxorubicin-based chemotherapy.MethodsWe performed a retrospective analysis on breast core biopsy tissue samples taken from 18 TNBC patients before they were treated with doxorubicin-based chemotherapy. CREB3L1 expression in the cancer cells was analyzed by immunohistochemistry and quantified using the Immunoreactive Score (IRS). Outcomes of the chemotherapy were measured by the residual cancer burden (RCB) system.ResultsCREB3L1 expression levels in TNBC responsive to doxorubicin-based chemotherapy (RCB class 0-2) were significantly higher than that in resistant cancers (RCB class 3) (unpaired two-tailed t test, p = 0.0005; Statistical power 99.8 at 95% confidence level). All cancers expressing higher levels of CREB3L1 (IRS 4-12) responded to doxorubicin-based chemotherapy, whereas all cancers resisting the treatment expressed lower levels of CREB3L1 (IRS 0-3).ConclusionsThese results suggest that CREB3L1 expression level may be used as a biomarker to identify TNBC patients who are more likely to benefit from doxorubicin-based chemotherapy.

show abstract

“…Ductal carcinoma in situ (DCIS) is a risk factor for incomplete resection of breast cancer. Detecting DCIS around breast cancer before treatment may therefore alter surgery [29] Wu et al [30] also considered the Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast. Literature indicates that about 30 percent of ductal carcinoma in situ lesions during a certain time become invasive breast cancer [19].…”

Section: Discussionmentioning

confidence: 99%

A Survival Analysis of Invasive Breast Cancer Patients with and Without in Situ Neoplasm

Atashgar¹

2018

IJSSAM

View full text Add to dashboard Cite

In situ neoplasm (or Carcinoma in situ (CIS)) is expression of malignant epithelial cells. This flat lesion is referred to as ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Considering neoplasm leads one to an effectiveness survival analysis compared to the case that neoplasm is not attended. The objective of this research is to analyze statistically survival of invasive breast cancer patients considering 1) with in situ neoplasm, and 2) without in situ neoplasm, and providing a comparative analysis. This study attempts to reveal that the both medical history (such as diabetes, hypertension, and internal glands disorders such as hypo-and hyperthyroidism) and extra capsular extension play important roles in the hazard function of a patient's survival analysis. This statistical study indicates that 1) the survival rate of breast cancer patients with in situ neoplasm is more than one who is not initially supported by invasive carcinoma, and 2) in the case of existence of the both in situ neoplasm and invasive malignancy, after the 4 th year, the life expectancy is increased compared to the one with only invasive malignant. The statistical analysis indicates that pathology type is recognized as a high hazard factor for a breast cancer patient.

show abstract

Update on Immunohistochemical Analysis in Breast Lesions

Cited by 25 publications

References 82 publications

Expression of E cadherin and Ki 67: Emerging Prognostic Markers in Triple-Negative Breast Cancer

Expression of E cadherin and Ki 67: Emerging Prognostic Markers in Triple-Negative Breast Cancer

CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy

A Survival Analysis of Invasive Breast Cancer Patients with and Without in Situ Neoplasm

Contact Info

Product

Resources

About